Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides

• Main Authors: Liu, J, Bhadra, M, Sinnakannu, J.R, Yue, W.L, Tan, C.W, Rigo, F, Ong, S.T, Roca, X
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: antisense oligonucleotide; BH3 protein; BIM protein; cis acting element; imatinib; protein tyrosine kinase inhibitor; RNA isoform; serine arginine rich splicing factor; alternative RNA splicing; apoptosis; Article; BIM gene; cancer adjuvant therapy; cancer resistance; chronic myeloid leukemia; chronic myeloid leukemia cell line; controlled study; DNA sequence; drug mechanism; enzyme inhibition; exon; gene deletion; gene switching; genetic association; genetic code; human; human cell; K-562 cell line; KCL-22 cell line; protein domain; RNA splicing
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/179546
• Institution: National University of Singapore

10.18632/oncotarget.20658